SuperGen, Warner-Lambert deal

SUPG acquired from Warner-Lambert the exclusive rights to the anticancer drug pentostatin in the U.S., Canada and Mexico for an undisclosed cash payment and shares of SUPG common stock. SUPG said the equity payment is less than 1 percent of the company's shares outstanding. Pentostatin is sold under the trade name Nipent to treat hairy cell leukemia, for which it has Orphan Drug status. It is now in Phase II clinical studies for rheumatoid arthritis.

SUPG is in the process of building a cancer sales force. Nipent will be the fourth product that its reps will sell, as it recently acquired three anticancer products from Barr Laboratories. ...